Please try another search
For the fiscal year ended 31 December 2015, NephroGenex Inc revenues was not reported. Net loss increased 36% to $22.9M. Higher net loss reflects Research and development - Balancing increase of 34% to $15M (expense), General and administrative - Balancing increase of 31% to $5.9M (expense), Interest expense increase from $140K to $565K (expense).
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -5.83 | -5.21 | -6.24 | -5.04 |
Net Income | -5.96 | -5.35 | -6.38 | -5.17 |
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Assets | 23.05 | 22.14 | 20.63 | 25.11 |
Total Liabilities | 11.9 | 10.71 | 12.27 | 10.68 |
Total Equity | 11.14 | 11.43 | 8.36 | 14.43 |
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -19.64 | -15.73 | -9.7 | -4.67 |
Cash From Investing Activities | 11.68 | 12.93 | 5.95 | 7.06 |
Cash From Financing Activities | 12.81 | 8.08 | -0.04 | 0 |
Net Change in Cash | 4.85 | 5.27 | -3.78 | 2.38 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review